C-KCW1Cytonics
A2M biologics, osteoarthritis, anti-protease
modulatingbiologic
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-KCW1
C-KCW1C-KCW1A2M biologics, osteoarthritis, anti-protease
0-100 chain-logic scale · 15 dimensions · scored on public evidence
The goal of this Phase 1 study is to investigate the safety of CYT-108, our experimental recombinant protease inhibitor drug candidate for osteoarthritis, in a population of patients suffering from osteoarthritis of the knee. The main questions this study aims to answer are: 1. are two doses of CYT-108, delivered 12 weeks apart, safe when injected directly into the joint? 2. does administration of CYT-108 result in a reduction in pain, stiffness, and improvement in daily physical function? Participants will either receive a placebo (Phosphate Buffer Saline, PBS) or CYT-108, and will be asked to report their pain/stiffness at weeks 1, 4, 8, 12, 16, and 26 (in a physician's office) after the initial injection, using a questionnaire to be provided by the physician. In addition to reporting the magnitude of pain, participants will also be asked about the onset of pain reduction. Researchers will compare the pain/stiffness scores between the CYT-108-treated to placebo-treated groups along the 26 week duration of the study. Participants will also receive blood draws along the course of the study, and researchers will analyze this blood for the presence of cartilage degradation product in attempt to identify "disease modification" (i.e., a reduction in cartilage degradation) in response to CYT-108 treatment.
The mechanism of Osteoarthritis (OA) is complex, however the investigators know that cartilage breakdown follows changes in certain cells in the cartilage called chondrocytes, leading to proteases that break down cartilage. There is a protein in the human blood called alpha-2-macroglobulin that can trap these proteases and prevent the breakdown of cartilage. Cytonics developed a device that use the patient's own blood to remove all cells and concentrate alpha-2-macroglobulin to be injected in the painful knee due to osteoarthritis.
Patients have a diabetic foot ulcer that is older than 4 weeks and has been treated with physician-selected standard of care treatment such as debridement, hydrogel or saline irrigation, primary dressing, and offloading will be randomized into one of two groups, the Standard of Care (SoC) or APIC-PRP + SoC. APIC-PRP has high level of platelets that produce growth factors that can help in wound healing.
Osteoarthritis (OA) is the irreversible degeneration of articular cartilage and underlying bone. It poses a major healthcare problem as it is the leading cause of joint disease and disability in the United States. It was traditionally thought that OA was a consequence of aging and joint trauma. However, it is now thought that OA is a result of the interplay of multiple genetic, biomechanical, and biochemical factors that disrupt the normal homeostasis of cartilage, bone, and synovium. OA is classified into two groups, primary and secondary. Primary OA is classically polyarticular and peripheral while secondary OA can commonly be attributed to a specific cause, limited to a singular joint, and a result of trauma. It is known as post-traumatic OA (PTOA). Other causes of secondary OA include congenital disorders, calcium pyrophosphate dehydrate deposition disease, and other diseases. Regardless of classification, genetic variation in the normal metabolism of cartilage and bone is thought to play a role in the progression of OA. Furthermore, the polyarticular presentation of primary idiopathic osteoarthritis suggests that it may have a stronger genetic component as compared to secondary OA, indicating a deviation from normal cartilage and bone homeostasis. Matrix metalloproteinases (MMP) and their inhibitors take part in the metabolism of cartilage and bone. MMPs are enzymes that catalyze the degradation of elements within joint spaces while their inhibitors cease this activity. Alpha-2-Macroglobulin (A2M) is a naturally-occurring plasma glycoprotein that functions throughout multiple tissues and extracellular spaces as a protease inhibitor but does not normally reach high levels within the intra-articular joint space. A2M is believed to modulate the systemic inflammatory response by its ability to bait, trap, and clear various MMPs and cytokines. Concentrated A2M directly addresses the roles of cytokines and catabolic enzymes known to participate in the development of osteoarthritis. Cytonics has shown that A2M can inhibit cartilage degradation in vitro. As the role of MMPs and protease inhibitors have emerged as key components of OA, the investigation of regulators of MMP has become of interest to elucidate the pathogenesis and possible novel treatments of OA. This study aims to measure and correlate the levels of alpha-2-Macroglobulin (A2M) in plasma and knee joint OA between primary post-traumatic (PTOA) and secondary osteoarthritis groups.
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
A major patent cliff is coming up for fast-growing Incyte CEO Bill Meury shares what's next for the biopharma company's R&D strategy and drug pipeline | CNBC Fast Money
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
8,500 Owners. $7M Raised. Thank YOU. Home About Credtrus Contact Us Privacy Policy & Terms Sign in Subscribe By Credtrus — 11 Sep 2025 8,500 Owners. $7M Raised. Thank YOU. Joey Bose here, President, CEO, and guy who is currently on his way to Jiu-Jitsu practice with a coffee in one hand and gratitude in the other. I just wanted to say this as plainly as possible: Thank you. Seriously. You helped us raise over $7 million, our biggest crowdfunding campaign yet, and more proof that we can subvert the standard biotech model and rely on the people to compete with Big Pharma. In just five
%PDF-1.7 %���� 1 0 obj >/Metadata 5931 0 R/ViewerPreferences 5932 0 R>> endobj 2 0 obj > endobj 3 0 obj >/Pattern >/XObject >/Font >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 960 540] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��VMo�8� ���T�4���M�f[l�:E� �����VV����Ȏ�"I{�͑��7�foۮZ�EgW���$��� �������$�_A=If� �-���]W�5[��=l�z���R �^��$M� ��1�p�+�i� :f �Q��u/)��\�e=��a��J�p���`;�B)T'rf5��BQD���$Q��AY�@`���/aa=I)�O!6 �����pvM�� ��Ǧ�;�����ͯ�%iܘ� �K�N���1�U�.��u�B6�-�j[5��'��� G���,=M��G2��Mo�-d&���,\x^��1 �sM
GoFundYourself: Medtech Crowdfunding Platform | Thomas Ross posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to Linked … this post Healthcare venture capital just hit a new level. Several significant fund closings reveal a massive surge of capital pouring into health innovation. This isn't just about more money; it's about a strategic shift. Primary Venture Partners closed their massive $625M Fund V. They're going nationwide, targeting AI, HealthTech, and Fintech with substantial $5-10M checks for early-stage companies. This signals a clear bet on AI revolutionizing healthcare. Yosemite, led b … ionizing healthcare. Yosemite, led by Reed Jobs, secured $200M for their second fund. They're uniquely blending venture capital with philanthropic grants. Their goal? To fast-track academic research into life-saving clinical breakthroughs. This hybrid model is fascinating. Sante Health Ventures II LP also closed their largest fund yet, a $330M Fund V. They're doubling down on Seed to Series B in Biotech, Medtech, and Digital Health, with a keen eye on AI-powered services and … niversities are stepping up. The University of Pennsylvania launched a $50M PxB Fund specifically for early-stage life science startups emerging from their ecosystem. This localized innovation support is crucial. And for specific diseases, dedicated funds are making waves. The T1D Fund manages over $200M, catalyzing over $1 billion in private capital for Type 1 Diabetes cures. Their venture philanthropy model is incredibly impactful. Finally, global pharma is joining the fray … al pharma is joining the fray. Servier Ventures, a new €200M (~$234M) evergreen fund from Servier, is focusing on early-stage European biotech and HealthTech. What does this all mean? The healthcare innovation landscape is maturing rapidly. Massive capital, strategic focus on AI, unique hybrid models, and institutional support are all converging.
Why This Biotech Play Just... - Investor's Business Daily Facebook Log In Investor's Business Daily's Post Investor's Business Daily Verified account May 4 · Shared with Public Why This Biotech Play Just Reentered Its Buy Zone investors.com The Entire XBI Is Today's IBD Stock Of The Day — Here's Why All reactions: 10 2 comments Like Comment Most relevant Karaj Sandhu Burj 6w
Cytonics Completes Phase 1 Study, Advances to Phase 2 | Cytonics Corporation posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, yo
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
CAREstream Group and Cytonics Corporation Agree to Global License Collaboration Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery All Multimedia All Photos All Videos M … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Life Sciences Funding Deals: Edgewise Therapeutics $2.65B | Windsor Bux posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agr … 0,365 followers 3w Edited Report this post L'Oréal ’s corporate venture capital fund BOLD, the venture fund of L’Oréal (Business Opportunities for L’Oréal Development) has invested in South Korean biotech company OliX Pharmaceuticals, Inc. . The developer of RNAi therapeutics, which are medicines that preemptively treat unwanted, disease-causing proteins, raised approximately KRW 110bn (US$71m) through a third-party allotment via newly issued common shares to strategic invest … ness 261,003 followers 2w Report this post L'Oréal 's corporate venture capital fund BOLD (Business Opportunities for L’Oréal Development) has invested in South Korean biotech company OliX Pharmaceuticals, Inc. . The developer of RNAi therapeutics, which are medicines that preemptively treat unwanted, disease-causing proteins, raised approximately KRW 110bn (US$71m) through a third-party allotment via newly issued common shares to strategic investors. Click the link below to … hrough a private placement, attracting investment from L'Oréal Groupe's venture fund BOLD and U.S.-based Weiss Asset Management as the RNA interference therapeutics developer advances its siRNA pipeline. OliX said it plans to use the proceeds to advance its siRNA-based drug development programs across multiple therapeutic areas, including ongoing collaborative research related to #skin and #hair conditions. #KBeauty # Guive Balooch # Dong-ki Lee https://lnkd.in/gWqExNCw OliX … Dong-ki Lee https://lnkd.in/gWqExNCw OliX raises ₩110 bil. from L'Oréal venture fund and Weiss Asset Management koreabiomed.com 1 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Kai Bouvier 1w Report this post #HealthcareMandA is surging. The #pharma industry saw $65 billion in deals for the first quarter of 2026, th
healthcare – Page 2 – Cytonics Corporation Skip to content Skip to footer Home About Us Vision Principles The Team Advisors Ambassadors Media Videos Social Media Events & Webinars Media Enquiries Science Osteoarthritis A2M – The Body’s Molecular Bodyguard Our Breakthrough – CYT-108 Scientific Publications Products & Pipeline APIC™ CYT-108 FACT™ Investors Corporate Overview Press Releases Milestones Presentations Intellectual Property Contact INVEST Home Science Osteoarthritis Therapeutic Platform Scientific Publications Pipeline Diagnostics Autologous A2M CYT-108 Investors … ent Phase 1 study focused on safety and efficacy, providing data for an FDA IND application and Phase 2 protocol. This milestone boosts prospects for a disease-modifying therapy and enhances shareholder value. Read More #47 🪙Cytonics Announces Launch of Regulation A+ Equity Crowdfunding Campaign to Fund Phase 2 Development Investor Relations , Our Story March 25, 2025 770 Views 0 Likes 0 Comments Cytonics is seeking $24 million to fund a Phase 2 Clinical Study for CYT-108, i
Cytonics - Most biotech companies are built for venture... Facebook Log In Cytonics's Post Cytonics June 16 at 3:58 PM · Shared with Public Most biotech companies are built for venture capital before they're built for patients. That shapes everything, which diseases get funded, which mechanisms get pursued, which patients get ignored. Cytonics took a different path. CYT-108 isn't a synthetic compound the industry invented and tried to force into a broken pathway. It's a recombinant upgrade of a protein your body already produces, A2M, your blood's natural defense again
Look Who Attends The Florida Venture Capital Conference! | Florida Venture Forum Events Press Passes Event Photos Sponsor Events 2027 Florida Venture Capital Conference Florida Early Stage Venture Conference Founders Investors & Service Providers Membership Resource Library News FL Innovation Connect About Partners Board and Committee The FLVEF Get Involved Subscribe to Updates Attend an Event Apply to Pitch Become A Member Contact Us Select Page Look Who Attends The Florida Venture Capital Conference! Partial list of past and currently registered conference attendees. A full list of 2024 … rman akoyaGO Alacriti Analytics Anatomie Anthemis – Female Innovators Lab Fund Aqualung Therapeutics ARCH Venture Partners Arcis Capital Partners Arsenal Growth Equity Astrocyte Pharmaceuticals Attorney Shield Inc Automated Imaging Diagnostics Avant Assurance Inc Avid Legal Azome Therapeutics Azul Baird Ballast Point Ventures Bamboozlers Spirits Banc of California BB Capital BB Therapeutics BDO USA Begin A Project Berger Singerman Berman Hopkins CPAs and Associates Bern … ms Capital Florida CFO Group Florida Department of Commerce/Florida Opportunity Fund Florida Funders Florida Gulfshore Capital Florida Opportunity Fund Florida Power & Light FloridaCommerce Floww.io Foley & Lardner Fox Rothschild Freebee Frontier Growth Fulcrum Equity Partners Gainfront Galaxy Diagnostics Georgia Institute of Technology Gobel Goodman Technologies Goodwin Procter Govo Venture Partners Greenberg Traurig Greenwood & Cavalier Greenwood and Cavalier Gr … d Massinvestor mavi.io MedBot Medxoom Medzoomer MemryX Mercato Partners Mercury Fund Miami Dave County ITC Miami-Dade Beacon Council Miami-Dade Innovation Authority MidCap/Apollo Mitochondrial Medicines Corp Montague Law Morris, Manning & Martin My bonum Myosin Therapeutics Naples Technology Ventures National Energy USA Nedge Computing Nelson Mullins NeuroGeneces NeuroSync New Enterprise Associates, Inc. New World Angels NextEquity Partners NextEra Energy, Inc. Noro-Mosel … Valley Bank Silicon Valley Bank / FCB Smart Inbound Websites Sontag Innovation Fund Sopris Capital SouthState Bank Space Florida Spectre Enterprises Inc. Spring Mountain Capital SRS Acquiom SSM Partners Stetson University StockSnips Stony Lonesome Group Strategic Lever LLC Streann Media SVB Swamp Cat Brewing Company Synchronyx Tamiami Angel Fund
26th Annual Thomas Jefferson University Spine Fellows Alumni Symposium - Thomas Jefferson University Continuing Professional Development - Continuing Education (CE) This live, in person course is designed exclusively for spine surgeons seeking active discussions concerning the care and management of patients suffering from spinal disorders and cervical and lumbar degenerative conditions.</p><p><strong>Successful Completion</strong><br>To successfully complete this activity, <u>the required evaluation must be completed no later than Friday, August 7, 2026</u>. Thereafter, t … s will be offered for failure to complete the required evaluation by the stated deadline.</p>" /> Neurological Surgery</Profession><Profession>Spinal/Peripheral Nerve Disorders</Profession" /> {1} ##LOC[OK]## {1} ##LOC[OK]## ##LOC[Cancel]## {1} ##LOC[OK]## ##LOC[Cancel]## << Back to Jefferson CPD Sign In Live Courses Online Courses RSS About Contact For Learners For Planners {1} ##LOC[OK]## {1} ##LOC[OK]## ##LOC[Cancel]## {1} ##LOC[OK]## ##LOC[Cancel]## New … Forgot Your Password? Forgot Your Password? Enter your Email address and click submit to have a login reset link sent to you. Back to Login {1} ##LOC[OK]## {1} ##LOC[OK]## ##LOC[Cancel]## {1} ##LOC[OK]## ##LOC[Cancel]## Create an Account: (All fields are required) Email: First Name: Last Name: Password: Password: Password Requirements Must be between 8 and 16 characters in length Must Contain at least 1 upper case character Must Contain at least 1 lower case character Must c … s will be offered for failure to complete the required evaluation by the stated deadline. Objectives At the conclusion of this activity, healthcare team members will be able to: Summarize the latest surgical techniques for the treatment of cervical and lumbar spine conditions, their indications, outcomes and evidence. Assess the benefits and disadvantages of the latest minimally invasive techniques and procedures designed to address lumbar spine conditions. Evaluate the utili … be used in Jefferson publications or on the Jefferson website. If you verbally submit any questions for Q&A sessions, you are agreeing to be recorded and to have that recording available in enduring materials. Once photographed, filmed, recorded, or videotaped, you waive the right of inspection or approval to which such images/recordings may
SVA Life Sciences is proud to be a sponsor and exhibitor at the South Florida Life Sciences Showcase. | Jason Oppmann LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or s
Biotech Success Defined by Patient Outcomes | Cytonics Corporation posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to
%PDF-1.4 %���� 2152 0 obj > endobj xref 2152 51 0000000016 00000 n 0000002425 00000 n 0000002588 00000 n 0000003837 00000 n 0000004449 00000 n 0000005010 00000 n 0000005487 00000 n 0000005659 00000 n 0000005848 00000 n 0000006027 00000 n 0000006078 00000 n 0000006193 00000 n 0000006300 00000 n 0000006850 00000 n 0000007476 00000 n 0000008028 00000 n 0000008127 00000 n 0000008755 00000 n 0000011860 00000 n 0000014364 00000 n 0000016611 00000 n 0000019535 00000 n 0000022235 00000 n 0000025072 00000 n 0000025755 00000 n 0000026164 00000 n 0000026277 00000 n 0000026384 00000 n 0000027045 00000 n 0 … le Lt RGB PROCESS 149 77 158 R=224 G=163 B=38 1 RGB PROCESS 224 163 38 Document application/pdf logo-button-22-gold-blue-1c proof:pdf xmp.did:ba8de65d-6f33-0e42-a250-ed9da5ac23dc uuid:6312709a-7839-40ed-acb8-60993219694a uuid:6f79589f-2540-400f-af1f-37acd9573dc2 uuid:43cf3882-9b15-4812-8e78-286b25e7d3a1 xmp.did:67EB79742FBEE611804DA1E2CF8A0EE6 uuid:6f79589f-2540-400f-af1f-37acd9573dc2 proof:pdf saved xmp.iid:36BBB118FDDFE211A241BCFC9193624D 2013-06-28T11:08:34-05:00 Adobe Ill … Adobe PDF library 15.00 endstream endobj 2191 0 obj > endobj 2192 0 obj >stream application/pdf ASIPPlogo-287-k-1 Adobe Illustrator CS2 2010-02-15T08:37:46-06:00 2012-05-17T15:56:34-05:00 2012-05-17T15:56:34-05:00 uuid:55A008A11B9611DFB6DAFAB250904561 uuid:3438d72f-7bb4-4286-b23a-e5393cea31b4 proof:pdf uuid:55A008A01B9611DFB6DAFAB250904561 uuid:55A0089F1B9611DFB6DAFAB250904561 Adobe PDF library 7.77 1 False False 8.500000 11.000000 Inches Black PANTONE 287 C PANTONE Reflex Bl … 00000 2.000000 Document endstream endobj 2193 0 obj > endobj 2194 0 obj >stream application/pdf icons-socialmedia-k-1 Adobe Illustrator CS5.1 2017-10-26T15:39:51-05:00 2017-10-26T15:39:51-05:00 2017-10-26T15:39:51-05:00 xmp.did:3A6B1ACF8DBAE711A930806F7725872C uuid:12259d47-9715-4c05-9a1d-c711b73f2590 proof:pdf uuid:D9E76F87B7F811DFB1FF93776A05C122 uuid:4aad9ba7-cb68-4284-984f-fcde037bee02 uuid:D9E76F87B7F811DFB1FF93776A05C122 uuid:D9E76F87B7F811DFB1FF93776A05C122 proof:pdf s … ����'+\���N��G�������0ĺO� endstream endobj 52 0 obj > endobj 53 0 obj >stream application/pdf gocana I:\Convention Planning\Floorplans\2020\Texas\asipp1-2004-hyadal\asipp1-2004-hyadal 8x11h. (1) 2020-02-26T13:21:59-08:00 PScript5.dll Version 5.2.2 2020-02-27T11:08:39-06:00 2020-02-27T11:08:39-06:00 Acrobat Distiller 20.0 (Windows) uuid:70bb96a4
Science – Cytonics Corporation Skip to content Skip to footer Home About Us Vision Principles The Team Advisors Ambassadors Media Videos Social Media Events & Webinars Media Enquiries Science Osteoarthritis A2M – The Body’s Molecular Bodyguard Our Breakthrough – CYT-108 Scientific Publications Products & Pipeline APIC™ CYT-108 FACT™ Investors Corporate Overview Press Releases Milestones Presentations Intellectual Property Contact INVEST Home Science Osteoarthritis Therapeutic Platform Scientific Publications Pipeline Diagnostics Autologous A2M CYT-108 Investors Press Presentatio
CYT-108 by Cytonics for Osteoarthritis: Likelihood of Approval Skip to site menu Skip to page content Switch language: .translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Pharma Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial Intelligence Corporate Governance Cloud Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insights Deals Jobs Filings Patents Social
Cytonics - Most biotech companies are built for venture... Facebook Log In Cytonics's Post Cytonics June 16 at 3:58 PM · Shared with Public Most biotech companies are built for venture capital before they're built for patients. That shapes everything, which diseases get funded, which mechanisms get pursued, which patients get ignored. Cytonics took a different path. CYT-108 isn't a synthetic compound the industry invented and tried to force into a broken pathway. It's a recombinant upgrade of a protein your body already produces, A2M, your blood's natural defense again
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Instagram Instagram Log In Sign Up Close Never miss a post from cytonics_corporation Sign up for Instagram to stay in the loop. Sign up Log in cytonics_corporation • Follow More options cytonics_corporation 13w Phase 1 complete. Safety established. Phase 2 underway. Platform advancing. This is where biotech starts to change. Not in theory - in data. As risk comes down, the opportunity doesn’t just improve - it expands. Each milestone strengthens the foundation, sharpens the model, and increases what this platform can unlock. This is what real progress looks like. Measured. Proven. Compounding.
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Nasdaq - 🔔Thank you for ringing the opening bell, Eton... Facebook Log In Nasdaq's Post Nasdaq Verified account December 6, 2018 · Shared with Public Thank you for ringing the opening bell, Eton Pharmaceuticals ! Eton is focused on bringing innovative, high-value 505(b)(2) products to patients. All reactions: 20 1 comment 3 shares Like Comment Most relevant Tyrone Omar *paid off 7y
404 – Cytonics Corporation 4 4 Page not found We’re sorry, but something went wrong. Homepage We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Ok
Cytonics vs Cytonics — Newsletter Sponsor Comparison | SponsorGap SponsorGap Find Sponsors Find Creators Tools Tools SponsorMyNewsletter Hot Get sponsors delivered to your inbox Free Search Engine Search 25k+ sponsor deals Sponsor Trends Trending brands by industry Compare Sponsors New Side-by-side sponsor analysis Ad Copy Library Real ads from top newsletters Sponsor Calendar Upcoming ad slot availability Datasets Software Sponsors SaaS & dev tool brands Ecommerce Sponsors DTC & retail brands Finance Sponsors Fintech & investment brands Crypto Sponsors Web3 & blockchain brands Pricing API Blo
253G2 1 tm2427963d11_253g2.htm 253G2 Filed Pursuant to Rule 253(g)(2) File No. 024-12533 OFFERING CIRCULAR DATED MARCH 17, 2025 Cytonics Corporation 658 West Indiantown Road, Suite 214, Jupiter, FL 33458 (443) 827-8135 www.cytonics.com UP TO 8,000,000 SHARES OF COMMON STOCK CO NSISTING OF 6,666,667 SHARES ISSUED FOR CASH CONSIDERATION AND 1,333,333 ISSUED AS BONUS SHARES Investors in this offering will grant an irrevocable voting proxy to the company’s President that will limit their ability to vote their shares of Common … nt is included in the Total Maximum offering amount since it counts towards the rolling 12-month maximum offering amount that the Company is permitted to raise under Regulation A. However, it is not included in the gross proceeds received by the Company. (4) The columns “Total Maximum with processing fee—Price to Public” and “Total Maximum with processing fee—Proceeds to issuer before expenses” include $4,000,000, the value of the Bo … its Minimum Target Amount, the Escrow Agent may hold a series of closings on a rolling basis at which the Company will receive the funds from the escrow agent and issue the shares to investors. If the Minimum Target Amount is not reached by March 13, 2028, all funds tendered by investors will be promptly returned to investors in this offering. The Company may undertake one or more closings on a rolling basis once the Minimum Target Amount is sold. After each closing, funds t … ORE THAN 10% OF THE GREATER OF YOUR ANNUAL INCOME OR NET WORTH. DIFFERENT RULES APPLY TO ACCREDITED INVESTORS AND NON-NATURAL PERSONS. BEFORE MAKING ANY REPRESENTATION THAT YOUR INVESTMENT DOES NOT EXCEED APPLICABLE THRESHOLDS, THE COMPANY ENCOURAGES YOU TO REVIEW RULE 251(d)(2)(i)(C) OF REGULATION A. FOR GENERAL INFORMATION ON INVESTING, THE COMPANY ENCOURAGES YOU TO REFER TO www.investor.gov. This offering is inherently risky. See “Ris … ort to be finalized in Q3 2025. Following conclusion of the trial, we expect to submit an Investigational New Drug application to the FDA in Q4 2025. There is no guarantee that we will be able to achieve these dates for conclusion of the Phase 1 clinical study and submission of the Investigational New Drug application. Before commercialization, w
404 – Cytonics Corporation 4 4 Page not found We’re sorry, but something went wrong. Homepage We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Ok
Raising Capital to Build and Strengthen at Cytonics | Joey Bose posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to Li … 5 and Social New Venture Challenge (SNVC) '25, has taken home the $75,000 grand prize at the Tulane Business Model Competition! The team, based at the UChicago Science Incubator , is developing rapid, at-home diagnostic tools to expand access to testing across a range of infectious diseases. Building on their earlier success with TiCK Test, Exactics is now advancing AVA, a modular diagnostic platform designed to make testing more accessible, scalable, and user-friendly. We’re
Science – Cytonics Corporation Skip to content Skip to footer Home About Us Vision Principles The Team Advisors Ambassadors Media Videos Social Media Events & Webinars Media Enquiries Science Osteoarthritis A2M – The Body’s Molecular Bodyguard Our Breakthrough – CYT-108 Scientific Publications Products & Pipeline APIC™ CYT-108 FACT™ Investors Corporate Overview Press Releases Milestones Presentations Intellectual Property Contact INVEST Home Science Osteoarthritis Therapeutic Platform Scientific Publications Pipeline Diagnostics Autologous A2M CYT-108 Investors Press Presentatio
Products & Pipeline – Cytonics Corporation Skip to content Skip to footer Home About Us Vision Principles The Team Advisors Ambassadors Media Videos Social Media Events & Webinars Media Enquiries Science Osteoarthritis A2M – The Body’s Molecular Bodyguard Our Breakthrough – CYT-108 Scientific Publications Products & Pipeline APIC™ CYT-108 FACT™ Investors Corporate Overview Press Releases Milestones Presentations Intellectual Property Contact INVEST Home Science Osteoarthritis Therapeutic Platform Scientific Publications Pipeline Diagnostics Autologous A2M CYT-108 Investors P
Investor Q&A: Why Invest In Cytonics? LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy Policy , and Cookie … developing CYT-108 through FDA clinical trials. Why doesn’t Johnson and Johnson fund your company, since they already have an interest in Cytonics? We maintain a relationship with JJDC, Johnson and Johnson’s corporate venture division that the Cytonics stock is housed within. They acquired our stock through a corporate acquisition in 2019, and may take interest in an investment once we have Phase 1 clinical data. Naturally, they will be the first strategic partner we solicit
Cytonics Corporation – Cytonics Corporation Skip to content Skip to footer Home About Us Vision Principles The Team Advisors Ambassadors Media Videos Social Media Events & Webinars Media Enquiries Science Osteoarthritis A2M – The Body’s Molecular Bodyguard Our Breakthrough – CYT-108 Scientific Publications Products & Pipeline APIC™ CYT-108 FACT™ Investors Corporate Overview Press Releases Milestones Presentations Intellectual Property Contact INVEST Home Science Osteoarthritis Therapeutic Platform Scientific Publications Pipeline Diagnostics Autologous A2M CYT-108 Investors Pres
#49 🦈 When a Shark Asks the Right Questions – Cytonics Corporation Skip to content Skip to footer Home About Us Vision Principles The Team Advisors Ambassadors Media Videos Social Media Events & Webinars Media Enquiries Science Osteoarthritis A2M – The Body’s Molecular Bodyguard Our Breakthrough – CYT-108 Scientific Publications Products & Pipeline APIC™ CYT-108 FACT™ Investors Corporate Overview Press Releases Milestones Presentations Intellectual Property Contact INVEST Close Home About Us Vision Principles The Team Advisors Ambassadors Media Videos Social Media Events &
Investors – Cytonics Corporation Skip to content Skip to footer Home About Us Vision Principles The Team Advisors Ambassadors Media Videos Social Media Events & Webinars Media Enquiries Science Osteoarthritis A2M – The Body’s Molecular Bodyguard Our Breakthrough – CYT-108 Scientific Publications Products & Pipeline APIC™ CYT-108 FACT™ Investors Corporate Overview Press Releases Milestones Presentations Intellectual Property Contact INVEST Home Science Osteoarthritis Therapeutic Platform Scientific Publications Pipeline Diagnostics Autologous A2M CYT-108 Investors Press Presentat … rial Cytonics Announces Launch of Regulation A+ Equity Crowdfunding Campaign to Fund Phase 2 Development Milestones 2006-2013 Foundation and Early Innovation Founded in 2006 as Gamma Spine, the company pioneered their first generation "APIC "therapy for osteoarthritis. The company was then rebranded as Cytonics Corporation in 2007. By 2013, APIC secured FDA 510(k) clearance as a PRP-based medical device. 2014-2015 Early Commercial and Scientific Progress APIC was out-licensed … harmacodynamic dose-optimizing study (Q3 2026) Prepare Investigational New Drug Application (IND) (Q3 2026) Hold Type C meeting with the FDA to get feedback on Phase 1b/2a trial design (Q4 2026) Phase 1b/2a d startup (Q4 2026) – first trial designed to measure disease-modification File IND with the FDA (Q1 2027) IND in effect Q1 2027 Phase 1b/2a First Patient In (Q2 2027) 2028 - 2029 Phase 1b/2a Last Patient In (Q4 2028) Last Patient Last Visit (Q1 2029) Clinical Study Report … potential: begin positioning for IPO, acquisition, or strategic partnership to fund Phase 3 pivotal studies Prepare regulatory submissions in US, EU, and select global market Continue to expand A2M development pipeline into other disease areas (e.g., oncology) Investor Presentation Investor Presentation – From scalpel to startup: a surgeon’s discovery. A biotech rebellion. This investor deck lays out how we’re developing the first disease-modifying therapy for osteoarthritis
New Jersey Employers | Biotech Careers Skip to main content Biotech Careers Contact Submit an Employer Contact Add an Employer Search Open main menu Contact Submit an Employer Contact Add an Employer Search Main navigation Careers Job Areas People Articles Videos Biotech Companies Biotech Jobs Business Areas US Biotech Employers Displaying 2501 - 2550 of 8430 biotech employer locations Filter the data by: Select State - Any - Alabama Alaska American Samoa Arizona Arkansas Armed Forces (AA) Armed Forces (AE) Armed Forces (AP) California Colorado Connecticut Delaware District of Columbia Florida
Investors – Cytonics Cytonics Engineering the Future of Joint Health with Molecular Precision About Our Story Become a Shareholder Business Of Biotech Science Corner Investor Relations Investors Corporate Overview Cytonics is a clinical-stage biotechnology company developing CYT-108, a genetically engineered Alpha-2-Macroglobulin (A2M) protein variant, designed to treat osteoarthritis (OA) at its molecular origins. Built on over 15 years of foundational science, Cytonics has pioneered the therapeutic use of A2M, a naturally occurring protease inhibitor, and engineered it into a recombina … further development. Upcoming Milestones Cytonics anticipates submitting an IND application to the FDA in 4Q25. The clinical operations team has expanded in anticipation of Phase 1b/2a trials in early 2026. The ongoing Reg A+ raise is expected to conclude in March 2026. @media (max-width: 1024px){ .twae-wrapper{–tw-ybx-size: 80px !important;}}@media (max-width: 767px){ .twae-wrapper{–tw-ybx-size: 80px !important}} Investor Presentation Investor Presentation – From
Cytonics begins Phase I trial of CYT-108 to treat knee osteoarthritis Skip to site menu Skip to page content Switch language: .translate --> CT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Approvals Operations Outsourced Services Supply Chain Data Management Medical Devices Themes Artificial Intelligence Cloud Corporate Governance Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insights Deals Jobs Filings Patents Social Media Companies Company A-Z Company Categories Produc … Chain Data Management Medical Devices Latest Ollin Biosciences secures $330m to fund Phase III OLN324 trials Viking Therapeutics commences Phase I trial of VK3019 Ascletis receives FDA clearance for Phase I trial of obesity treatment Themes Sections Artificial Intelligence Cloud Corporate Governance Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Foreign Direct Investment Latest How wearables can unlock their full potentia
Cytonics Funded Through Crowdfunding | Joey Bose posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User A … and timelines that don’t always align with how we wanted to build. We chose to fund Cytonics through crowdfunding instead. To date, that’s brought in over $25M from thousands of individual investors. What that changes is who you’re accountable to, and how decisions get made. It allows us to take a more measured approach, protect the direction of the science, and avoid optimizing purely for short-term outcomes. It’s not the conventional model. But it’s been the right one for … , has received a $35,000 follow-on investment from the Buffalo Innovation Seed Fund – an early-stage, venture capital fund supporting high-growth companies in WNY. Finta – a fundraising workspace using AI to help manage investor relationships – is the third Cultivator graduate to receive follow-on seed funding through UB Business and Entrepreneur Partnerships. 👉 Learn more about the BISF https://lnkd.in/e5TeWJHP 20 Like Comment Share Copy LinkedIn Facebook X To view or add … re excited to announce the successful fundraise for Kline Hill Cendana Partners Fund II L.P. (“KHCP II”) at $400 million as covered by Secondaries Investor today. The oversubscribed fundraise is a testament to Kline Hill's and Cendana’s successful strategy and partnership approach to acquiring limited partner interests in mature early-stage venture capital funds. Kline Hill’s deep domain expertise in secondaries and Cendana’s focus on very early-stage VC funds enables KHCP II … ecapital #fundrais Kline Hill and Cendana raise $400m for second VC secondaries fund secondariesinvestor.com 151 3 Comments Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Kelly Holman 1mo Report this post Kline Hill’s deep domain expertise in secondaries and Cendana’s focus on very early-stage VC funds enables KHCP
#49 🦈 When a Shark Asks the Right Questions – Cytonics Cytonics Engineering the Future of Joint Health with Molecular Precision About Our Story Become a Shareholder Business Of Biotech Science Corner Investor Relations Investor Relations , Our Story #49 🦈 When a Shark Asks the Right Questions Published by Joey Bose on May 14, 2025 Earlier this week, Cytonics CEO Joey Bose sat down with Kevin O’Leary * — the outspoken investor and Shark Tank personality known for cutting through hype and getting straight to the point. The topic? How a small biotech company is doing what Big Pharma hasn’
Cytonics - Dr. Gaetano Scuderi, Founder and President of... Facebook Log In Cytonics's Post Cytonics February 21, 2018 · Shared with Public Dr. Gaetano Scuderi, Founder and President of Cytonics, was honored to be a guest speaker last week at The Orthobiologic Singularity's annual event in Broomfield, Colorado. He was invited by Interventional Orthopedics Foundation and Dr. Centeno to present on the topic "Cytokine Therapy - From A2M to IRAP to Exosomes - Do We Even Need The Cells?" To learn more about Cytonics, visit: http://cytonics.com/ All reactions: 15 2 shares Like Co
A heartfelt message from our Founder, Dr. Gaetano Scuderi. From the very beginning, Cytonics has been about more than just developing a breakthrough therapy - it’s been about building a movement. Every single investor who has joined us has played a role in pushing this mission forward. Dr. Scuderi shares his gratitude to the thousands of investors who believe in CYT-108 and our vision to change the future of osteoarthritis treatment. Thank you for believing in us. Thank you for investing in the future. Together, we’re building something extraordinary. Don't miss out. Our current raise clo
CAREstream Group and Cytonics Corporation Agree to Global License Collaboration – CAREstream America (855) 892-3872 About Solutions ALPHA2ACTIVE™ Adinizer body-jet® evo body jet® eco for Aesthetics CAREguardpro™, HME’s, & Filters CAREfilter™ CAREprp™ CARErover™ and Adapter Arm Celltermi HS and NX Plus Micronized Fat Pro-Nox TM Serres Fluid Management System Single Use Injection Kits VeinViewer® Flex VeinViewer® Vision2 Resources Webinars Events Vault Collection The Stream Connect SHOP ONLINE! CAREstream Group and Cytonics Corporation Agree to Global License Collaboration We are exci
EX1A-6 MAT CTRCT 20 tm2014693d1_ex6-5.htm EXHIBIT 6.5 Exhibit 6.5 EXCLUSIVE LICENSE AGREEMENT FOR MANUFACTURING, SALES, MARKETING, AND DISTRIBUTION IN THE VETERINARY MARKET Between Cytonics Corporation and Astaria Global, LLC Dated: June 30, 2019 1 Exclusive License Agreement for Manufacturing, Sales, Marketing, and Distributing in the Veterinary Market This agreement (the “Agreement”), made effective as of the 30th … “ IDE ” shall mean any Investigational Device Exemption application, as contemplated by Section 505(i) of the United States Federal Food, Drug, and Cosmetic Act, as amended from time to time, and the regulations promulgated thereunder, filed with the FDA pursuant to Part 812 of Title 21 of the U.S. Code of Federal Regulations, including any amendments thereto. References herein to IDE shall include, to the extent applicable, any comparable filing(s) ou … p; “ IND ” shall mean any Investigational New Drug application, as contemplated by Section 505(i) of the United States Federal Food, Drug, and Cosmetic Act, as amended from time to time, and the regulations promulgated thereunder, filed with the FDA pursuant to Part 312 of Title 21 of the U.S. Code of Federal Regulations, including any amendments thereto. References herein to IND shall include, to the extent applicable, any comparable filing(s) ou … nsferable, exclusive, license for the APIC System, without the right to sell or grant sublicenses without the expressed written consent of Cytonics, and such consent may not be unreasonably 6 withheld or delayed unless the new licensee is unable or ill-equipped to perform Commercially Reasonable Efforts due to reasons including, but not limited to, an insufficient business plan, inexperienced management, ongoing legal disputes, etc. For the avoidance of d … y selling the APIC System or allowing the APIC System to be sold for use in any application other than for Veterinary Applications. 8 j. not manufacturing marketing, selling, or distributing a product that is directly competitive to the APIC System, except for APIC New Products, with r
Cytonics Selects CARA Life Sciences Platform for Rapid eTMF System Implementation | CARA Life Sciences Platform Platform Solutions Applications & Registrations Submission Planning & Tracking Events, Activities & Commitments Product Management including IDMP, SPOR, xEVMPD Health Authority Correspondence Submission Archive Submission Documents Promotional Materials Medical Device Submissions Labelling SPOR Subscription Quality Events CAPAs Change Controls Deviations Management Complaints Management Quality Documents Management Audit & Inspection Management Batch Records Management Learning Manag … irements—user-friendly, compliant, and ready to go in record time.” CARA’s eTMF application delivers a fully compliant, audit-ready environment for managing clinical trial documentation, supported by robust metadata management, workflow automation, and seamless integration capabilities. It also includes DIA reference model alignment, automated trial and site setup, and an integrated site portal for streamlined collaboration. We’re proud to support Cytonics in their mission to
Cytonics Corporation | MTEC MTEC Focus Areas Who we serve Solicitations Patents About Us Explore Join MTEC Log In Life Sciences / Companies Cytonics Corporation Cytonics is a biotechnology research and development company specializing in developing diagnostics and therapeutics for osteoarthritis and other musculoskeletal diseases. Their mission is to eradicate osteoarthritis pain and improve quality of life through innovative biologic therapies. They have developed products such as the FACT diagnostic test, the autologous A2M therapy (APIC™), and are pursuing pre-clinical studies for their lea … on Show More (3) Show less News & Updates Cytonics Awarded Phase 2 NIH SBIR Grant Cytonics received a second award notice from the NIH to study and commercialize its FACT assay, a diagnostic biomarker for radicular pain, with a total value of $1.6M over two years. The grant supports ongoing research including a 100 patient study at Stanford University. Cytonics Announces FDA Approval of an Investigational New Drug Application for the APIC Cell-Free System Cytonics announc
#cytonics #biotech #healthspan #osteoarthritis #movement #wellness #futureofmedicine #a2m #scienceforgood #regenerativemedicine | Gaetano Scuderi, MD LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn B
A heartfelt message from our Founder, Dr. Gaetano Scuderi. From the very beginning, Cytonics has been about more than just developing a breakthrough therapy - it’s been about building a movement. Every single investor who has joined us has played a role in pushing this mission forward. Dr. Scuderi shares his gratitude to the thousands of investors who believe in CYT-108 and our vision to change the future of osteoarthritis treatment. Thank you for believing in us. Thank you for investing in the future. Together, we’re building something extraordinary. Don't miss out. Our current raise clo
Cytonics - 🤝 Invest like a VC! 🌍 Equity crowdfunding is... Facebook Log In Cytonics's Post Cytonics May 18, 2024 · Shared with Public Invest like a VC! Equity crowdfunding is the democratization of investing, giving you access to early-stage opportunities normally reserved for the “big boys”. Let’s dive into the nuts and bolts of Cytonics’ capital raise! You've learned about our research in regenerative medicine, but you might have questions about becoming a shareholder and equity crowdfunding. What is Equity Crowdfunding? Equity Crowdfunding, or “Regulation CF,” democratizes inves
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Cytonics Announces Launch of Regulation A+ Equity Crowdfunding Campaign to Fund Phase 2 Development Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery All Multimedia All … RSS Cytonics Announces Launch of Regulation A+ Equity Crowdfunding Campaign to Fund Phase 2 Development News provided by Cytonics Corporation Mar 25, 2025, 09:30 ET Share this article Share to X Share this article Share to X Cytonics Seeks $24 million to pursue FDA Phase 2 Clinical Study of CYT-108, the Company's Novel Therapy for Osteoarthritis JUPITER, Fla. , March 25, 2025 /PRNewswire/ -- Cytonics today announced that it is launching an offering of securiti … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Lock in up to 30% bonus shares with Cytonics investment | Joey Bose posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree t … t of a £2.5m seed funding round. Alstin is a €175m Munich-based venture capital fund investing in high-growth European B2B software companies. This transaction marks its first steps into the UK market, backing Round Financial’s fintech platform supporting treasury and cash management for startups and SMEs. Congratulations to Alstin and the Round Financial team on this exciting next phase of growth. Reflecting on the transaction, the Alstin team commented: “A great support in … more weight. You don't get a second shot at a first impression with a top-tier fund. The founders closing rounds right now aren't necessarily building better products. They're showing up more prepared. They know the fund's thesis before the call. They have a clean data room ready to share. They track every investor conversation so nothing falls through the cracks. That's the difference between a term sheet and a polite pass. We used SuperFunding AI to close our pre-seed roun … s joins Dogpatch Labs on April 14 for a session on how their €200m pan-European fund makes Seed and Series A fintech bets across payments, regulation, and financial infrastructure. In conversation with Patrick Walsh , Hugo Bongers will walk through how they evaluate opportunities, how AI is changing underwriting, and where they have conviction. Motive has backed companies including Fenergo, Global Shares, and Alchelyst in Ireland, alongside Nelly, Bunch, and Pliant across Eur … ls: Target: Vennre Acquirer/Investor: Vision Ventures (VV) and anb capital seed Fund (Co-leads), with participation from Sanabil Investments , ACE & Company , Plus VC (+VC) , and strategic angels. Value: £7 million Advisor: Not specified Market Context: This strategic investment, structured as a hybrid of equity and debt, underscores the sign
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Cytonics | Biotech Careers Skip to main content Biotech Careers Contact Submit an Employer Contact Add an Employer Search Open main menu Contact Submit an Employer Contact Add an Employer Search Main navigation Careers Job Areas People Articles Videos Biotech Companies Biotech Jobs Business Areas Cytonics Hired a Community College Student Website: Cytonics Business Area(s) Diagnostics Therapeutics Description Cytonics is a research and development company dedicated to discovering and developing therapeutics based on the protease inhibitor Alpha2 Macroglobulin (A2M). They have discovered a uniq
Cytonics concludes enrolment in Phase I knee osteoarthritis trial Skip to site menu Skip to page content Switch language: .translate --> CT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Approvals Operations Outsourced Services Supply Chain Data Management Medical Devices Themes Artificial Intelligence Cloud Corporate Governance Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insights Deals Jobs Filings Patents Social Media Companies Company A-Z Company Categories Product & … Chain Data Management Medical Devices Latest Ollin Biosciences secures $330m to fund Phase III OLN324 trials Viking Therapeutics commences Phase I trial of VK3019 Ascletis receives FDA clearance for Phase I trial of obesity treatment Themes Sections Artificial Intelligence Cloud Corporate Governance Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Foreign Direct Investment Latest How wearables can unlock their full potentia
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
%PDF-1.3 %��������� 3 0 obj > stream x+TT(T06�32006S��350�40S051�3��4V077ѳ�42R(JUW�*�K( �1��J�U���5Tp���)X endstream endobj 1 0 obj > endobj 4 0 obj > >> endobj 5 0 obj > stream ����JFIFdd��C��C���:"�� ���}!1AQa"q2���#B��R��$3br� %&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz��������������������������������������������������������������������������� ���w!1
Cytonics - Most biotech companies are built for venture... Facebook Log In Cytonics's Post Cytonics June 16 at 3:58 PM · Shared with Public Most biotech companies are built for venture capital before they're built for patients. That shapes everything, which diseases get funded, which mechanisms get pursued, which patients get ignored. Cytonics took a different path. CYT-108 isn't a synthetic compound the industry invented and tried to force into a broken pathway. It's a recombinant upgrade of a protein your body already produces, A2M, your blood's natural defense again
JavaScript is disabled In order to continue, we need to verify that you're not a robot. This requires JavaScript. Enable JavaScript and then reload the page.
JavaScript is disabled In order to continue, we need to verify that you're not a robot. This requires JavaScript. Enable JavaScript and then reload the page.
Cytonics CEO and Jiu Jitsu master discuss innovation and health. | Joey Bose posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, yo … UBLI 154,531 followers 8mo Report this post How do we innovate, manufacture and apply our products to make a difference in the world? 🎬 Our new film “How we power Test & Measurement” showcases exactly that. The film captures what drives us every day: people, performance, passion, and partnership. From laboratories to production lines, from surgery rooms to scientific research, our solutions support industries where precision and reliability are essential. ⚙️✨ A special t
PART II AND III 2 tm2014693d4_partiiandiii.htm PART II AND III As filed with the Securities and Exchange Commission on June 16, 2020 File No. 024-11196 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 1-A/A (Amendment No. 2) REGULATION A OFFERING CIRCULAR UNDER THE SECURITIES ACT OF 1933 CYTONICS CORPORATION (Exact name of issuer as specified in its charter) Florida (State of other jurisdiction of incorporation or organization) 658 West Indiantown Road, Suite 214 Jupiter, Florida 33458 Phone: (561) 406-2864 (Address, … ore than 10% of the greater of your annual income or net worth. Different rules apply to accredited investors and non-natural persons. Before making any representation that your investment does not exceed applicable thresholds, we encourage you to review Rule 251(d)(2)(i)(C) of Regulation A. For general information on investing, we encourage you to refer to www.investor.gov . An investment in the Shares is subject to certain risks and should be made only by persons or … The platelet rich plasma is mixed with autograft and/or allograft bone prior to application to a bony defect for improving bone graft handling characteristics.” 3 Over 7,000 patients have been treated by the APIC-PRP system. Cytonics engineered a smaller, more efficient, and less expensive version of the APIC-PRP system (the “APIC Mini”) designed to provide smaller doses for applications such as spinal discs and facet joints, small joint … n mind, employing a 2-step process with utilizing a proprietary filter. The FDA application for this product has been reviewed, and Cytonics plans on issuing a response in late 2020. We anticipate a similar labeling to APIC-PRP. “The Cytonics Autologous Platelet Integrated Concentrate (APIC-Mini) is indicated for the rapid preparation of autologous platelet rich plasma from a small sample of blood at the patient's point of care. The platelet rich plasma is mixed … The platelet rich plasma is mixed with autograft and/or allograft bone prior to application to a bony defect for improving bone graft handling characteristics.” Our current focus is on the development of a synthetic A2M variant (“CYT-108”), based upon the protein structure of the naturally-occurring A2M molecule that has
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Invest in Cytonics | The First Drug to Potentially Cure Osteoarthritis Unlock up to 15% Bonus Shares 00 Days 00 Hrs 00 Mins 00 Secs Traction Problem Solution Perks Updates Roadmap Team FAQs Discussion Webinar Sign Up Invest Now Invest In A Potential Cure For Osteoarthritis Now we're advancing toward the next phase of FDA clinical trials in a $560B market that has no cure. Phase 1 FDA human clinical trial completed, safety confirmed. Partnered with leading researchers at Stanford Uni and Scripps. Investing today at a $160M valuation, projected to reach $4B at Phase 2 completion. Invest Now … harmacodynamic dose-optimizing study (Q3 2026) Prepare Investigational New Drug Application (IND) (Q3 2026) Hold Type C meeting with the FDA to get feedback on Phase 1b/2a trial design (Q4 2026) File IND with the FDA (Q1 2027) Phase 1b/2a startup (Q4 2026) – first trial designed to measure disease-modification IND in effect Q1 2027 Phase 1b/2a First Patient In (Q2 2027) 2028–2029 Phase 1b/2a Last Patient In (Q4 2028) Last Patient Last Visit (Q1 2029) Clinical Study Report for … potential: begin positioning for IPO, acquisition, or strategic partnership to fund Phase 3 pivotal studies Prepare regulatory submissions in US, EU, and select global market Continue to expand A2M development pipeline into other disease areas (e.g., oncology) 2025 Completed first-in-human Phase 1 clinical trial No drug-related adverse events were detected, confirming CYT-108’s safety Prepared Phase 1b/2a trial protocol Onboarded statistician, regulatory consultant, and medi … ng with FDA on Phase 1b/2a trial design (Q1 2027) File Investigational New Drug Application (Q4 2027) Phase 1b/2a startup, first trial designed to measure disease-modification (Q2 2027) 2029+ First patient treated in Phase 1b/2a study (Q1) Interim data readout (Q3) Begin positioning for IPO, acquisition, or major partnership Complete Phase 1b/2a and prepare Clinical Study Report for FDA review (Q4) Prepare regulatory submissions in US, EU, and select global markets Continue e … re in escrow, your funds will be promptly refunded to you upon cancellation. To submit a request to cancel your investment please email: [email protected] How do I keep up with how the company is doing? At a minimum, the company will be filing with the SEC and posting on its website an annual report, along with certified financial stat
Cytonics Announces Completion Of Enrollment For Phase 1 Clinical Study Evaluating CYT-108, A Novel Recombinant Protease Inhibitor, In Patients Suffering From Osteoarthritis Of The Knee - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Sh … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Cytonics Announces Completion Of Enrollment For Phase 1 Clinical Study Evaluating CYT-108, A Novel Recombinant Protease Inhibitor, In Patients Suffering From Osteoarthritis Of The Knee September 6, 2024 | 6 min read Twitter LinkedIn Facebook Email Print Top-line results from Phase 1 study expected in seco … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Cytonics Announces Successful Completion of Phase 1 Study for First Nine Patients in CYT-108 Clinical Trial - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends C … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Cytonics Announces Successful Completion of Phase 1 Study for First Nine Patients in CYT-108 Clinical Trial January 21, 2025 | 6 min read Twitter LinkedIn Facebook Email Print – No adverse events reported; CYT-108 progressing as a potential disease-modifying therapy for osteoarthritis – JUPITER, Fla. , Ja … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Cytonics Announces that Last Patient Completes Last Visit in First-in-Human Phase 1 Clinical Trial for CYT-108 as a Treatment for Osteoarthritis - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manu … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Cytonics Announces that Last Patient Completes Last Visit in First-in-Human Phase 1 Clinical Trial for CYT-108 as a Treatment for Osteoarthritis April 1, 2025 | 6 min read Twitter LinkedIn Facebook Email Print - Topline results expected by end of Q2 2025 – - Phase 1 enrolled 22 patients to examine the saf … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin